July 2026 FDA Recall Azelaic Acid by Glenmark Pharmaceuticals Inc., Usa
D-0731-2026 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Glenmark Pharmaceuticals Inc., Usa on July 23, 2026 for the product Azelaic Acid. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0731-2026

Reason for Recall
CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.
Initiated
07-23-2026
Reported
08-05-2026
Quantity
N/A

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Glenmark Pharmaceuticals Inc., USA
Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Nationwide within the United States.
Azelaic Acid Gel, 15%, 50 gram tubes, For Topical Use only, Rx only, Distributed by: Glenmark Pharmaceuticals Inc., USA, Elmwood Park, NJ 07407, NDC 68462-626-52.

Batch or Lot Expiration Information

Lot# : 19260937A, Exp. Date February 2028; 19261225A, 19261185A, Exp. Date March 2028; 19261664A, 19261682A, Exp. Date April 2028.

Affected Packages Involved in this Recall